NCT00640809 - Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole | Biotech Hunter

Enrollment

408

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

April 30, 2004

Conditions

Bowel Diseases, Inflammatory

Interventions

DRUG

Celecoxib

200 mg oral capsule twice daily for 2 weeks

OTHER

Placebo

Matched placebo for 2 weeks

DRUG

Ibuprofen plus Omeprazole

ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks

Trial Locations (12)

10021

Pfizer Investigational Site, New York

33173

Pfizer Investigational Site, Miami

33458

Pfizer Investigational Site, Jupiter

60612

Pfizer Investigational Site, Chicago

61107

Pfizer Investigational Site, Rockford

85259

Pfizer Investigational Site, Scottsdale

90033

Pfizer Investigational Site, Los Angeles

90073

Pfizer Investigational Site, Los Angeles

92037

Pfizer Investigational Site, La Jolla

97239

Pfizer Investigational Site, Portland

48109-0362

Pfizer Investigational Site, Ann Arbor

37232-5280

Pfizer Investigational Site, Nashville

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY